Jpmorgan Chase & CO Sangamo Therapeutics, Inc Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SGMO
# of Institutions
115Shares Held
56.4MCall Options Held
576KPut Options Held
1.17M-
Wasatch Advisors Inc Salt Lake City, UT19.4MShares$36.6 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.6MShares$18 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.85MShares$9.12 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$8.84 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.35MShares$4.43 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $294M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...